Citations

Clear

73 citation(s) found for "Schaeffer, A J".

Blocking RAN translation without altering repeat RNAs rescues C9ORF72 -related ALS and FTD phenotypes
Jiang, Xin , Schaeffer, Laure, Patni, Divya, Russo, Tommaso , Lee, Chao-Zong, Aguilar, Corey, Marques, Christine , Jansen-West, Karen, Hruška-Plocháň, Marián , Ray-Soni, Ananya, Lim, Su Min , Held, Aaron , Yue, Mei, Otero, Paula Castellanos, Aryal, Sandeep , Beaussant, Hortense D. A. M. , Basu, Himanish , Takakuwa, Hiro , Daughrity, Lillian M. , Ramesh, Nandini , Costa, Paulo J. da, Quadros, Ana Rita A. A., Nolan, Matthew , Reyes, Charles Jourdan , Wheeler, Hayden J., Moran, Laura C. , Griesman, Grant , Wymann, Benjamin , Trombetta, Bianca A. , Lopez-De-Silanes, Emma Sofia , Canori, Michael, Silva, Yasmim Vieira Souza Da, Eriani, Gilbert , Albers, Mark W. , Arnold, Steven E. , Song, Yuyu , Jain, Ankur, Chiu, I., Zhang, Yong-Jie, Gao, Fen‐Biao , Wainger, Brian J. , Polymenidou, Magdalini , Petrucelli, Leonard, Martin, Franck , Lagier-Tourenne, Clotilde, Lagier‐Tourenne, Clotilde , Jansen-West, Karen R , Castellanos Otero, Paula, Da Costa, Paulo , A A Quadros, Ana Rita , Eriani, Gilbert , Albers, Mark W , Arnold, Steven E , Song, Yuyu , Chiu, Isaac M , Zhang, Yong-Jie , Gao, Fen-Biao , Wainger, Brian J , Polymenidou, Magdalini , Petrucelli, Leonard , Martin, Franck , Lagier-Tourenne, Clotilde , Lee, Chao-Zong , Jansen‐West, Karen , Ray-Soni, Ananya, Krishnan, Gopinath , Jain, Ankur , Petrucelli, Leonard

Mayo Clinic

Science | February 5, 2026 | Volume: 391 | Issue: 6785 | Pages: No page available

10.1126/science.adv2600 | PMID 41643021 Get It

GGGGCC (G 4 C 2 ) repeat expansion in C9ORF72 is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Toxicity is thought to result from the accumulation of either repeat RNAs and/or dipeptide repeat proteins (DPRs) translated from repeat-containing transcripts through repeat-associated non-AUG (RAN) translation. To disentangle RNA from DPR toxicity, we mutated a CUG codon predominantly used to initiate DPR translation from all three reading frames. This mutation disrupted DPR synthesis while preserving the expression of repeat-containing RNAs. Despite the accumulation of RNA foci, behavioral deficits and pathological abnormalities, including p-TDP-43 inclusions, STING activation, motor neuron loss, neuroinflammation, and increased plasma neurofilament concentration, were alleviated in C9ORF72 mice. Base editing of the CUG codon also improved molecular phenotypes and survival in patient induced pluripotent stem cell–derived neurons, which highlights the potential of therapeutically targeting DPR production rather than repeat RNAs.
Clinical Practice Guidelines by Infectious Diseases Society of America 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections--Introduction and Methods
Trautner, Barbara W. , Cortés-Penfield, Nicolás , Gupta, Kalpana , Moran, Gregory J. , Colgan, Richard, Ashraf, Muhammad Salman , Connolly, S.J., Grigoryan, Larissa, Nicolle, Lindsay, Schaeffer, A J, Yawetz, Sigal, Lavergne, Valéry , Grigoryan, Larissa , Grigoryan, Larissa , Schaeffer, Anthony , Hirsch, Elizabeth B. , Horstman, Molly J. , O’Horo, John C. , Drekonja, Dimitri Maximilian , Huttner, Angela , Lazenby, Gweneth B. , Nicolle, Lindsay E., Schaeffer, Anthony , Trautner, Barbara W

Mayo Clinic

Clinical Infectious Diseases | December 11, 2025 | Volume: 82 | Issue: Supplement_3 | Pages: i24-i35

10.1093/cid/ciaf459 | PMID 41467387 Get It

Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections – Timing of Intravenous to Oral Antibiotics Transition for Complicated Urinary Tract Infections
Trautner, Barbara W. , Cortés-Penfield, Nicolás , Gupta, Kalpana , Moran, Gregory J. , Colgan, Richard, Ashraf, Muhammad Shamvil, Connolly, S.J., Grigoryan, Larissa , Lazenby, Gweneth B. , Nicolle, Lindsay E., Schaeffer, Anthony , Yawetz, Sigal, Lavergne, Valéry , Grigoryan, Larissa , Schaeffer, Anthony , Gupta, Kalpana , Hirsch, Elizabeth B. , Horstman, Molly J. , O’Horo, John C. , Ashraf, Muhammad S, Drekonja, Dimitri Maximilian , Huttner, Angela , Trautner, Barbara W

Mayo Clinic

Clinical Infectious Diseases | December 11, 2025 | Volume: 82 | Issue: Supplement_3 | Pages: i68-i78

10.1093/cid/ciaf461 | PMID 41414903 Get It

Abstract Background These recommendations provide guidance on the optimal timing for transitioning from intravenous to oral antibiotics in patients with complicated urinary tract infection (cUTI), especially in presence of associated Gram-negative bacteremia. Methods The panel's recommendations are based upon evidence derived from systematic literature reviews which focused on comparative benefits and harms of transitioning to oral therapy versus continuing parenteral therapy of the total duration of treatment, including publications since 2000. These recommendations adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Results The guidelines panel suggests transitioning to oral antibiotics in patients with cUTI who are clinically improving, able to take medication, and for whom an effective oral option is available, rather than continuing parenteral therapy for the remaining treatment duration, regardless of the presence of associated Gram-negative bacteremia. An effective oral option needs to be active against the causative pathogen and achieve therapeutic levels in the urine and relevant tissue. Conclusions Parenteral and oral antibiotics used to complete treatment courses for cUTI provide similar efficacy and adverse events, especially in the context of shorter duration of therapy. This recommendation places a high value on reducing avoidable intravenous catheter-related adverse events, costs, and resources, as well as taking into account practical aspects of antibiotic administration.
Clinical Practice Guidelines by Infectious Diseases Society of America (IDSA): 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections--Duration of Antibiotics for Complicated UTI
Trautner, Barbara W. , Cortés-Penfield, Nicolás , Gupta, Kalpana , Horstman, Molly J. , Moran, Gregory J. , Colgan, Richard, Ashraf, Muhammad Shamvil, Connolly, S.J., Grigoryan, Larissa , Lazenby, Gweneth B. , Nicolle, Lindsay E., Schaeffer, Anthony , Yawetz, Sigal, Lavergne, Valéry , Grigoryan, Larissa , Schaeffer, Anthony , Gupta, Kalpana , Hirsch, Elizabeth B. , O’Horo, John C. , Ashraf, Muhammad S, Drekonja, Dimitri Maximilian , Huttner, Angela , Trautner, Barbara W

Mayo Clinic

Clinical Infectious Diseases | December 11, 2025 | Volume: 82 | Issue: Supplement_3 | Pages: i79-i88

10.1093/cid/ciaf462 | PMID 41419448 Get It

Abstract Background These recommendations provide guidance on the optimal duration of antibiotics in patients with complicated urinary tract infection (cUTI), especially in presence of associated Gram-negative bacteremia. Methods The panel's recommendations are based upon evidence derived from systematic literature reviews which focused on comparative benefits and harms of shorter (5–7 days) vs prolonged (10–14 days) duration of antibiotics, including publications since 2000. These recommendations adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Results The guidelines panel suggests that patients with cUTI who are improving on effective therapy can be treated with shorter duration of antimicrobials (either 5–7 days of a fluoroquinolone or 7 days of a non-fluoroquinolone) rather than longer courses of antibiotics, regardless of the presence of associated Gram-negative bacteremia. An effective antimicrobial agent achieves therapeutic levels in the urine and relevant tissue and is active against the causative pathogen. However, men with febrile UTI in whom acute bacterial prostatitis is suspected may benefit from a longer treatment duration (10–14 days), and a short courses of oral beta lactams may require higher doses for efficacy. Conclusions Shorter durations of antibiotics for cUTI provide similar efficacy as longer courses, except in men with febrile UTI in whom acute bacterial prostatitis is suspected. This recommendation places a high value on antibiotic stewardship considerations as well as reducing the burden of antimicrobial administration from a healthcare perspective and reducing the burden of taking antibiotics from a patient perspective.
Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections–Selection of Antibiotic Therapy for Complicated Urinary Tract Infections
Trautner, Barbara W. , Cortés-Penfield, Nicolás W, Gupta, Kalpana, Hirsch, Elizabeth B, Horstman, Molly, Moran, Gregory J, Colgan, Richard, O’Horo, John C, Ashraf, Muhammad S, Connolly, Shannon, Drekonja, Dimitri, Grigoryan, Larissa , Huttner, Angela, Lazenby, Gweneth B, Nicolle, Lindsay, Schaeffer, Anthony , Yawetz, Sigal, Lavergne, Valéry, Lazenby, Gweneth B. , Grigoryan, Larissa , Trautner, Barbara W , Cortés-Penfield, Nicolás W, Gupta, Kalpana, Hirsch, Elizabeth B, Horstman, Molly, Moran, Gregory J, Colgan, Richard, O’Horo, John C, Ashraf, Muhammad S, Connolly, Shannon, Drekonja, Dimitri, Huttner, Angela, Lazenby, Gweneth B, Nicolle, Lindsay, Schaeffer, Anthony , Yawetz, Sigal, Lavergne, Valéry, Moran, Gregory J.

Mayo Clinic

Clinical Infectious Diseases | December 11, 2025 | Volume: 82 | Issue: Supplement_3 | Pages: i36-i67

10.1093/cid/ciaf460 | PMID 41419213 Get It

Abstract Background These recommendations address the empiric choice of antibiotics in suspected complicated urinary tract infection (cUTI). Issues to balance include the need for appropriate initial empiric antimicrobial therapy, the patient's severity of illness, and antimicrobial stewardship concerns. Methods The panel's recommendations are based upon evidence derived from systematic literature reviews that focused on comparative benefits and harms of classes of antibiotics approved for cUTI, starting with publications from 2008 onwards, and our review of predictors of resistance in uropathogens included references identified since 2000. These recommendations adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Results The guidelines panel suggests initially selecting among preferred empiric antibiotic choices rather than alternative options, stratified for the patient's severity of illness and antimicrobial stewardship considerations. When choosing among these antibiotics for a specific patient, the guideline panel suggests a 4-step process to account for changing resistance patterns and individualized patient needs. The steps are: (1) assess the severity of illness (for initial prioritization of antibiotics), (2) consider patient-specific risk factors for resistant uropathogens (for optimization of coverage), (3) evaluate other patient-specific considerations (to reduce the risk of adverse events), and (4) for patients with sepsis, consult a relevant local antibiogram if available (to further improve the likelihood of giving appropriate empiric therapy). Lastly, the guideline panel suggests selecting definitive effective therapy with a targeted spectrum based on the result of the urine culture. Conclusions Many of the classes of antibiotics approved to treat cUTI demonstrate similar efficacy as other classes of antibiotics in randomized controlled trials. Bacterial resistance prevalence is always changing, and new antibiotics will be developed. In this context, the guidelines panel provides recommendations for choosing empiric antibiotic therapy for cUTI that will help clinicians decide among available antibiotic options at the point of care.
Assessment of PARP1 mRNA expression as prognostic of aggressive pathology and adverse outcomes, and as predictor of response to PARP inhibition in castration-sensitive prostate cancer.
Alshalalfa, Mohammed , Hao, Yangyang , Proudfoot, J. , Schaeffer, Edward M. , Karnes, R. Jeffrey , Antonarakis, Emmanuel S. , Teply, Benjamin A. , Davicioni, Elai , Spratt, Daniel E. , Hwang, Justin H. , Lotan, Tamara Levin , Marshall, Catherine H.

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 5_suppl | Pages: 202-202

10.1200/jco.2025.43.5_suppl.202 Get It

202 Background: While several PARP inhibitors are approved in combination with hormonal therapies for metastatic castrate resistant prostate cancer (CRPC), their use in castrate sensitive prostate cancer (CSPC) is understudied. We previously reported that olaparib monotherapy (without ADT) shows significant clinical activity in BRCA2 -altered patients with biochemically recurrent (BCR) prostate cancer. Here, we explored prognostic and predictive PARP-related mRNA biomarkers derived from primary prostate tumors. Methods: We characterized the expression of 16 PARP transcripts using a cohort of 52,266 radical prostatectomy (RP) specimens (2016-2024) undergoing Decipher prostate genomic classifier testing (Veracyte Inc). Transcriptome-wide mRNA expression data as well as baseline clinical/pathologic factors were retrieved from the Decipher GRID database (NCT02609269). Associations between high PARP expression (top 25%), baseline factors, and gene signatures were examined using logistic regression. We assessed the association between PARP expression and distant metastases in 3 retrospective cohorts (n= 545, 855, and 325). Finally, we evaluated PARP expression in our prior phase II trial (NCT03047135, n=39) of olaparib monotherapy in the setting of BCR following RP. Results: Higher mRNA levels of PARP1 , 2 , 8 and 14 showed strong associations (all P <0.001) with known adverse prognostic factors such as very-high Decipher score (>0.85), high Gleason grade (GG5) and non-organ confined disease (EPE, SVI and LNI), while higher PARP6 and 7 expression were associated with more favorable disease characteristics. High PARP1 expression was positively correlated with DNA-repair deficiency (r=0.77) and tumor immune microenvironment (r=0.62) signatures. In 3 independent retrospective cohorts of intermediate-high risk PCa patients, higher PARP1 expression was strongly associated with development of distant metastases after RP (HR 1.70, 1.81, and 1.67 respectively; all P <0.05). Finally, in our phase II trial of patients with BCR who received olaparib monotherapy, PARP1 (but not PARP2 ) expression from RP was 1.5-fold higher in samples with BRCA2 mutations (median 0.416 vs 0.276, P =0.01) and was associated with overall improved PSA progression-free survival (continuous variable, HR 0.55, P =0.01) and longer time to next systemic treatment (continuous variable, HR 0.66, P =0.02). Conclusions: High PARP1 mRNA expression, measured at RP, is associated with aggressive disease biology and greater risk of metastasis. However, high PARP1 (but not PARP2 ) levels are associated with improved response to PARP inhibition in the setting of BCR prostate cancer. Future trials testing PARP (including PARP1-selective) inhibitors in the CSPC space should consider measuring PARP1 mRNA levels in addition to BRCA1/2 mutation status. Clinical trial information: NCT02609269 , NCT03047135 .
Contributions of neurologists to diagnostic timelines of ALS and thinkALS as an early referral instrument for clinicians
Dave, Kuldip D. , Yersak, Jill, Krauss, Ramona , Heiman‐Patterson, Terry , Lomen‐Hoerth, Catherine , Selig, Wendy , Paul, Ilisa Halpern, Schaeffer, Melody , Garcia-Trujillo, Brittany, Waldo, Daniel R., Thakur, Neil , Babu, Suma , Oskarsson, Björn

Mayo Clinic

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | December 10, 2024 | Volume: 26 | Issue: 3-4 | Pages: 215-224

10.1080/21678421.2024.2432034 | PMID 39654532 Get It

BRCA1, BRCA2 , and Associated Cancer Risks and Management for Male Patients
Shevach, Jeffrey , Castro, Elena , Couch, Fergus J. , Domchek, Susan M., Eeles, Rosalind A. , Lin, Daniel W., Morgan, Todd M. , Offit, Kenneth, Schaeffer, Edward M. , Szymaniak, Brittany M. , Eeles, Rosalind A , Morgan, Todd M , Cheng, Heather H. , Couch, Fergus J. , Giri, Veda N. , Hall, Michael J. , King, Mary‐Claire , Lin, Daniel W., Loeb, Stacy , Offit, Kenneth, Pritchard, Colin C. , Vassy, Jason L. , Katona, Bryson W , Maxwell, Kara N.

Mayo Clinic

JAMA Oncology | July 25, 2024 | Volume: 10 | Issue: 9 | Pages: 1272

10.1001/jamaoncol.2024.2185 | PMID 39052257 Get It

Importance Half of all carriers of inherited cancer-predisposing variants in BRCA1 and BRCA2 are male, but the implications for their health are underrecognized compared to female individuals. Germline variants in BRCA1 and BRCA2 (also known as pathogenic or likely pathogenic variants, referred to here as BRCA1/2 PVs) are well known to significantly increase the risk of breast and ovarian cancers in female carriers, and knowledge of BRCA1/2 PVs informs established cancer screening and options for risk reduction. While risks to male carriers of BRCA1/2 PVs are less characterized, there is convincing evidence of increased risk for prostate cancer, pancreatic cancer, and breast cancer in males. There has also been a rapid expansion of US Food and Drug Administration–approved targeted cancer therapies, including poly ADP ribose polymerase (PARP) inhibitors, for breast, pancreatic, and prostate cancers associated with BRCA1/2 PVs. Observations This narrative review summarized the data that inform cancer risks, targeted cancer therapy options, and guidelines for early cancer detection. It also highlighted areas of emerging research and clinical trial opportunities for male BRCA1/2 PV carriers. These developments, along with the continued relevance to family cancer risk and reproductive options, have informed changes to guideline recommendations for genetic testing and strengthened the case for increased genetic testing for males. Conclusions and Relevance Despite increasing clinical actionability for male carriers of BRCA1/2 PVs, far fewer males than female individuals undergo cancer genetic testing. Oncologists, internists, and primary care clinicians should be vigilant about offering appropriate genetic testing to males. Identifying more male carriers of BRCA1/2 PVs will maximize opportunities for cancer early detection, targeted risk management, and cancer treatment for males, along with facilitating opportunities for risk reduction and prevention in their family members, thereby decreasing the burden of hereditary cancer.